Guidelines: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==== Prostate ==== | ==== Prostate ==== | ||
* | * [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]] | ||
* [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]] | * [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]] | ||
*[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]] | *[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]] | ||
| Line 17: | Line 17: | ||
* '''<span style="color:#008000">NEW!</span>''' [[Microscopic Hematuria (2025)]] | * '''<span style="color:#008000">NEW!</span>''' [[Microscopic Hematuria (2025)]] | ||
* '''<span style="color:#008000">NEW!</span>''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]] | * '''<span style="color:#008000">NEW!</span>''' [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2024 AUA)|Non-muscle Invasive Bladder Cancer (2024)]] | ||
* | * [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]] | ||
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | *[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | ||
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | *[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | ||
| Line 39: | Line 39: | ||
==== Andrology ==== | ==== Andrology ==== | ||
* [[Testosterone Deficiency (2024)]] | |||
* [[Priapism|Priapism (2021)]] | * [[Priapism|Priapism (2021)]] | ||
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | * [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | ||
* [[Peyronie's Disease (2015)]] | * [[Peyronie's Disease (2015)]] | ||
| Line 46: | Line 46: | ||
==== Functional ==== | ==== Functional ==== | ||
* '''<span style="color:#008000">NEW!</span>''' [[Incontinence after Prostate Therapy (2024)]] | |||
* [[AUA: Overactive Bladder (2019)|Overactive Bladder (2024)]] | |||
* [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]] | * [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]] | ||
*[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | *[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | ||
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]] | *[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]] | ||
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]] | * [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]] | ||
| Line 74: | Line 75: | ||
* [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]] | * [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]] | ||
* | *[[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]] | ||
*[[AUA: Urotrauma (2020)|Urotrauma (2020)]] | *[[AUA: Urotrauma (2020)|Urotrauma (2020)]] | ||
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]] | * [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]] | ||
| Line 81: | Line 82: | ||
==== Contribute ==== | ==== Contribute ==== | ||
* Incontinence after Prostate Therapy (2024 Amendment) | |||
*Incontinence after Prostate Therapy | |||
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment) | *Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment) | ||
*Management of LUTS attributed to BPH (2023 Amendment) | *Management of LUTS attributed to BPH (2023 Amendment) | ||
| Line 113: | Line 112: | ||
==== Kidney ==== | ==== Kidney ==== | ||
* '''<span style="color:#008000">NEW!</span>''' [[CUA: Cystic Renal Lesions (2023)|Cystic Renal Lesions (2023)]] | |||
* [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]] | * [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]] | ||
* [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]] | * [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]] | ||